Also found in: Medical.
ILARISIntrinsic Landscape Aesthetic Resource Information System
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Medicine company Novartis reported on Friday that it has received three simultaneous approvals from the US Food and Drug Administration (FDA) for the expanded use of Ilaris (canakinumab) for the treatment of three rare and distinct types of Periodic Fever Syndromes.
Walker noted, however, that the Ilaris registry now has at least 14 CAPS patients who ran into serious trouble after receiving the vaccine.
Grant Jones/Jones & Jones; ILARIS; the Puget Sound plan.
Canakinumab is marketed by Novartis as Ilaris and is already approved for cryopyrin-associated periodic syndromes, familial Mediterranean fever, juvenile idiopathic arthritis, and other rare autoimmune inflammatory diseases.
M2 PHARMA-September 26, 2016-Novartis wins three new US FDA approvals for the expanded use of Ilaris for treating rare Periodic Fever Syndrome conditions
Canakinumab (Ilaris) was approved in June 2009 for the treatment of a rare disorder, cryopyrin-associated periodic syndromes (CAPS).
BASEL, Switzerland -- The biotechnology medicine Ilaris (canakinumab) has passed another milestone with a recommendation for approval in the European Union (EU) as a treatment for patients with a lifelong and potentially fatal auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS).
He said the ACALM findings are particularly intriguing when considered in the context of the 2017 results of the landmark CANTOS trial, in which canakinumab (Ilaris), a targeted anti-inflammatory agent that inhibits the interleukin-1 beta innate immunity pathway, reduced recurrent ischemic events in post-MI patients who had high systemic inflammation as evidenced by their elevated C-reactive protein level but a normal-range LDL cholesterol (N Engl J Med.
It was recently reported that Novartis had used its PRV to obtain priority review of a supplemental biologic application (sBLA) for Ilaris (carta-kinumab), a humanized antibody.
M2 PHARMA-September 27, 2011-MHLW approves Novartis' Gilenya in MS, Ilaris in CAPS(C)2011 M2 COMMUNICATIONS